You are here: Home ยป Archives for Mergers and Acquisitions (M&A)

Cellebrite to Acquire Corellium

TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 05, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm–based virtualization software. This combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm–based IoT device. Customers across public safety, defense, intelligence and private sectors will benefit from:

  • Accelerated identification of mobile vulnerabilities and exploits
  • Industry–first ability to visualize and interact with virtual devices as if they were physically present – aiding prosecutors, juries, investigators and developers
  • Increased efficiency, speed and efficacy of DevSecOps across all Arm–based devices
  • Arm–native and dynamic Mobile Pen Testing

“Leading edge technology matters,” said Thomas E. Hogan, Cellebrite’s interim chief executive officer. “Corellium has built an industry–unique virtualization platform that will ultimately help Cellebrite customers secure both their communities and institutions. The power of this combination goes beyond their technology and includes the addition of some of the brightest minds in vulnerability research, malware analysis and security testing. We could not be more excited about adding the Corellium team to the Cellebrite family. The combination of our respective talent and IP changes the game in the efficient securing and analysis of all Arm–based devices which are pervasive across a vast range of applications from cloud to edge.”

“The combination of Cellebrite’s commitment to innovation and its focus on public safety and security made this the perfect home for our people and our technology,” said Chris Wade, Corellium’s founder and chief technology officer, who will join Cellebrite as chief technology officer. “With Cellebrite’s offerings, users have ‘blueprints’ — technical schematics of what is on a device. With the addition of Corellium’s technology, users will virtually walk through the device, explore every room and open every door safely and without altering a thing in a forensically sound manner. I am personally thrilled to join Tom’s team as the new chief technology officer and to work closely with the Cellebrite research and development team.”

“Arm is the world’s most pervasive computing platform, and as AI continues to transform markets and deliver new experiences, the safety and security of our devices has never been more critical,” said Mohamed Awad, SVP and GM, Infrastructure, Arm. “Corellium's innovative Arm–based virtualization solutions leverage the unique footprint Arm has from cloud to edge, and we value their contributions as part of the ecosystem building the future of computing on Arm.” 

The acquisition of Corellium is expected to broaden Cellebrite’s TAM in both the public and private sectors. In the public sector, Corellium’s technology and talent will further enhance and broaden Cellebrite’s Digital Investigation Platform, while Corellium’s solution for mobile vulnerability research is expected to increase Cellebrite’s offerings for customers in the defense and intelligence sector. In the private sector, Corellium’s virtualization platform is expected to extend Cellebrite’s reach beyond eDiscovery and corporate investigation use cases through powerful virtualization solutions that enable development and security professionals to design the next generation of high–performance, secure mobile applications, IoT devices and automotive systems.

Cellebrite intends to acquire Corellium for an enterprise value of $170 million in cash with $20 million converted to equity at closing. Corellium securityholders will receive up to an additional $30 million in cash based on the achievement of certain performance milestones over the next two years. The deal is expected to close this summer, subject to approval of the Committee on Foreign Investment in the United States and other customary closing conditions. Cellebrite plans to provide additional information about Corellium’s anticipated financial contribution after the transaction closes.
       
J.P. Morgan Securities LLC is acting as exclusive financial advisor to Corellium.

Finally, Cellebrite is approaching the conclusion of its thorough CEO search process. The Company expects and plans to announce the appointment of the permanent CEO in conjunction with or prior to the mid–August disclosure of its second quarter 2025 results.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite’s AI–powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite’s digital forensic and investigative solutions—available via cloud, on–premises, and hybrid deployments—to close cases faster and safeguard communities.  To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com, and find us on social media @Cellebrite.

About Corellium
Corellium is the leader in Arm hypervisor virtualization, helping security and developer teams build, test, and secure software for mobile, automotive, and IoT devices using the power of virtual hardware. Over 500 organizations, governments, and security practitioners worldwide rely on Corellium’s virtualization solutions to enhance security testing and streamline DevOps. By providing highly performant, scalable, and precise virtual models, Corellium enables new capabilities not possible with physical hardware. Corellium previously raised $25M in a Series A round, led by Paladin Capital Group with participation from Cisco Investments.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, this combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm–based IoT device; with the addition of Corellium’s technology, users will virtually walk through the device, explore every room and open every door safely and without altering a thing in a forensically sound manner; Chris Wade’s prospective appointment as chief technology officer; the acquisition of Corellium is expected to broaden Cellebrite’s TAM in both the public and private sectors; in the public sector, Corellium’s technology and talent will further enhance and broaden Cellebrite’s digital forensics capabilities while Corellium’s solution for mobile vulnerability research is expected to increase Cellebrite’s offerings for customers in the defense and intelligence sector; in the private sector, Corellium’s virtualization platform is expected to extend Cellebrite’s reach beyond eDiscovery and corporate investigation use cases through powerful virtualization solutions that enable development and security professionals to design the next generation of high–performance, secure mobile applications, IoT devices and automotive systems; the timing associated with closing the transaction; Corellium earning up to an additional $30M in cash based on the achievement of certain performance milestones over the next two years; and the potential impact of the transaction on the Company’s 2025 revenue, annual recurring revenue (ARR), adjusted EBITDA, operating profitability and earnings are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on April 27, 2023 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media 
Jackie Labrecque
Sr. Manager of Content Strategy and Operations
[email protected]
+1 771.241.7010

Investor Relations 
Andrew Kramer 
Vice President, Investor Relations 
[email protected] 
+1 973.206.7760 


GLOBENEWSWIRE (Distribution ID 9463719)

Anaqua acquiert RightHub pour accélérer sa croissance mondiale

BOSTON, 15 mai 2025 (GLOBE NEWSWIRE) — Anaqua, l'un des principaux fournisseurs de technologies innovantes et de gestion de la propriété intellectuelle (PI), a annoncé aujourd'hui l'acquisition de RightHub®, un fournisseur de logiciels et de services de gestion de la PI. Cette acquisition s'inscrit dans la continuité de la stratégie d’Anaqua qui vise à fournir des solutions adaptées aux besoins de ses clients dans divers secteurs à travers le monde. Elle viendra également renforcer sa présence au Royaume–Uni, en Suède et au Danemark.

La plateforme IA native de RightHub, conçue pour répondre aux besoins des cabinets d'avocats et des entreprises de taille moyenne, restera une marque distincte qui viendra compléter l’offre des plateformes logicielles de gestion de la PI existantes d’Anaqua : AQX® et PATTSY WAVE®. Anaqua intégrera l'ensemble de ses données et services liés à la propriété intellectuelle dans RightHub afin d'offrir des avantages supplémentaires à ses clients. Anaqua continuera plus largement à tirer parti des composants et services partagés entre l'ensemble de ses solutions et s'engage à poursuivre le développement de chacune de ses plateformes logicielles de gestion PI.

« Nous sommes ravis d'accueillir RightHub au sein d’Anaqua. Nous partageons une volonté profonde de fournir au marché de la propriété intellectuelle les meilleures solutions logicielles, adaptées aux besoins spécifiques des professionnels de ce domaine au sein d'organisations de différents types et de différentes tailles », a déclaré Justin Crotty, PDG d’Anaqua. « RightHub complète exceptionnellement bien Anaqua, en apportant des experts passionnés du secteur de la propriété intellectuelle et une philosophie axée sur le client qui renforceront encore la présence d’Anaqua dans la région EMEA, en particulier au Royaume–Uni et dans les pays nordiques. »

Toni Nijm, cofondateur et PDG de RightHub, intégrera l'équipe de direction d’Anaqua. Toni Nijm possède une longue et brillante carrière dans le domaine de la propriété intellectuelle. Il a été avocat spécialisé en brevets, cadre supérieur dans le secteur des solutions de propriété intellectuelle (il a occupé les postes de directeur des produits, directeur de la technologie et directeur de la stratégie) et entrepreneur en série avec iPendo® et maintenant RightHub.

Justin Crotty a ajouté : « Je suis ravi que Toni Nijm apporte son expertise du secteur et son expérience à Anaqua en tant que membre de notre équipe dirigeante. Cela sera extrêmement bénéfique tant pour nos collaborateurs que pour nos clients. »

Toni Nijm a déclaré : « Les professionnels de la propriété intellectuelle sont constamment sous pression pour trouver des moyens d'innover et de travailler plus efficacement. Nous sommes ravis de rejoindre Anaqua afin de répondre ensemble aux besoins des professionnels de la PI avec des outils intuitifs, agiles et collaboratifs, alimentés par l'intelligence artificielle, pour améliorer leur réussite. Notre équipe suit Anaqua depuis de nombreuses années et se réjouit de mettre en œuvre une vision commune visant à développer des solutions technologiques qui répondent aux besoins en constante évolution du marché de la propriété intellectuelle. »

« RightHub est le complément idéal d'Anaqua », a déclaré Aditya Desaraju, Directeur général, Nordic Capital Advisors. « Ensemble, Anaqua et RightHub continueront à transformer la gestion de la propriété intellectuelle et à apporter des avantages concrets à leurs clients dans le monde entier. L'étendue et la profondeur de l'organisation et de ses offres sont inégalées dans le secteur. »

A propos d’Anaqua
Anaqua, Inc. est un fournisseur de premier plan de solutions et services technologiques intégrés de gestion de la propriété intellectuelle (PI) pour les entreprises et les cabinets de conseils. Ses plateformes logicielles, AQX®, PATTSY WAVE® et RightHub®, combinent les meilleurs outils pour définir une stratégie de propriété intellectuelle avisée. Ses technologies, qui reposent notamment sur des workflows et des capacités d’analyses avancées, offre un environnement de travail intelligent conçu pour prendre de meilleures décisions et optimiser les opérations de PI. Aujourd'hui, près de la moitié des 100 premiers déposants de brevets américains et des marques mondiales, ainsi qu'un nombre croissant de cabinets de conseils dans le monde utilisent les solutions Anaqua. Plus de deux millions de décisionnaires, avocats, parajuristes, gestionnaires et innovateurs utilisent la plateforme pour leurs besoins de gestion de la PI. Le siège de la société est situé à Boston, avec des bureaux aux Etats–Unis, en Europe, en Asie et en Australie. Pour plus d’informations, veuillez consulter le site anaqua.com ou LinkedIn.

A propos de RightHub
RightHub est une entreprise européenne dont la mission est d'améliorer l'infrastructure mondiale de protection des innovations. RightHub transforme radicalement le quotidien des professionnels de la propriété intellectuelle. Plutôt que de passer un temps considérable à effectuer des tâches administratives sans valeur ajoutée et à passer d'une application à l'autre, les professionnels de la propriété intellectuelle peuvent désormais gérer leurs activités quotidiennes sur une plateforme unique qui les connecte à leurs partenaires du monde entier, tout en intégrant les données et les services pertinents à chaque contexte et processus du cycle de vie de la propriété intellectuelle. La plateforme horizontale de RightHub offre aux titulaires de propriété intellectuelle et aux cabinets spécialisés dans ce domaine un moyen moderne et transparent d'utiliser et de payer les logiciels et services liés à la propriété intellectuelle. Pour plus d'informations, veuillez consulter le site www.righthub.com.

Contact presse :
Nancy Hegarty
VP, Marketing, Anaqua
+1–617–375–2655
[email protected]


GLOBENEWSWIRE (Distribution ID 9452228)

Anaqua Acquires RightHub to Accelerate Global Growth

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Anaqua, a leading provider of innovation and intellectual property (IP) management technology, today announced that it has acquired IP management software and services provider RightHub®. The acquisition represents a continuation of Anaqua’s strategy to deliver solutions positioned to meet the needs of customers in various segments worldwide and strengthens its organizational footprint in the UK, Sweden, and Denmark.

RightHub's AI–native platform, which has been designed to meet the needs of mid–size law firms and corporations, will remain a distinct brand complementing Anaqua's existing IP management software platforms, AQX® and PATTSY WAVE®. Anaqua will integrate its full range of IP data and services into RightHub to deliver additional benefits to its customers. More broadly, Anaqua will continue to leverage shared components and services across all of its solutions and is committed to the continued development of each IP Management software platform.

“We are thrilled to welcome RightHub to Anaqua. We share a deep commitment to providing the IP market with best–in–class, software–driven solutions that are tailored to meet the specific needs of IP practitioners in organizations of different types and sizes,” said Justin Crotty, CEO of Anaqua. “RightHub complements Anaqua exceptionally well, bringing passionate IP industry experts and a client–focused philosophy that will further bolster Anaqua's EMEA presence, particularly in the UK and Nordic region.”

Toni Nijm, Co–Founder and CEO of RightHub, will become a member of the Anaqua Executive Management Team. Toni has a long and successful track record in the IP space – as a patent attorney, as a senior executive within the IP solutions industry holding titles of Chief Product Officer, Chief Technology Officer, and Chief Strategy Officer, and as a serial entrepreneur with iPendo® and now RightHub.

Added Justin Crotty: “I am delighted that Toni will be bringing his vast industry experience and expertise to Anaqua as a senior member of our team. This will be of tremendous benefit both to our people and our clients.”

Toni Nijm commented: “IP professionals are constantly under pressure to find ways to innovate and work more efficiently. We are excited to join Anaqua to collectively address the needs of IP professionals for intuitive, nimble, and collaborative tools powered by AI to drive their business outcomes. Our team has followed Anaqua for many years and looks forward to executing against a shared vision of developing technology–first solutions that meet the ever–evolving needs of the IP market.”

“RightHub is the perfect addition to Anaqua,” said Aditya Desaraju, Managing Director, Nordic Capital Advisors. “Together, Anaqua and RightHub will continue to transform IP management and provide tangible benefits to IP customers worldwide. The organization’s breadth and depth and its offerings are unmatched in the industry.”

About Anaqua
Anaqua, Inc. is a premier provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software platforms, AQX®, PATTSY WAVE®, and RightHub® offer best practice workflows with big data analytics and tech–enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision–making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over two million IP executives, attorneys, paralegals, administrators, and innovators use the platforms for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Asia, and Australia. For additional information, please visit anaqua.com, or on Anaqua's LinkedIn.

About RightHub
RightHub is a European–based company on a mission to upgrade the global infrastructure for protecting innovations. RightHub radically transforms the day–to–day experience of being an IP professional. Rather than spending a significant amount of time dealing with non–value administrative tasks and jumping between multiple applications, IP professionals are now able to manage their daily work activities in a single platform that connects them to partners around the globe while integrating relevant data and services into each context and process of the IP lifecycle. RightHub’s horizontal platform provides both IP owners and IP firms with a modern and transparent way of consuming and paying for IP software and services. For more information, please visit www.righthub.com

Company Contact:
Nancy Hegarty
VP, Marketing, Anaqua
617–375–2655
[email protected]


GLOBENEWSWIRE (Distribution ID 9452228)

Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET

  • Affirmation de son leadership dans la production de l’isotope lutétium–177
  • Renforcement de son expertise en R&D et consolidation de son pipeline innovant
  • Extension de sa couverture géographique et de sa chaîne d’approvisionnement en imagerie nucléaire SPECT et TEP

PARIS, 29 mars 2025 (GLOBE NEWSWIRE) — Curium Pharma (“Curium”), leader mondial de la médecine nucléaire, annonce franchir un nouveau cap en achevant l’acquisition d’Eczacıbaşı–Monrol Nuclear Products Co. (Monrol), acteur clé du secteur basé à Istanbul, en Turquie.

Cette acquisition lui permet de revoir sa capacité de production de lutétium–177 (Lu–177) à la hausse pour répondre à une demande mondiale grandissante pour cet isotope. Elle garantit également l’approvisionnement nécessaire au futur lancement de ses traitements au Lu–177 pour le cancer de la prostate (en cours de développement) et les tumeurs neuroendocrines (en attente de validation).

Monrol vient compléter les fortes capacités de recherche et développement (R&D) de Curium et accompagner le développement constant de son portefeuille et de son pipeline de produits théranostiques innovants. Dans un avenir proche et sous réserve des approbations réglementaires, Curium envisage de déployer le générateur de Ga–68 de Monrol à l’échelle mondiale.

L’empreinte géographique complémentaire en TEP et SPECT de Monrol permet à Curium d’enrichir davantage son offre. Assortie de 12 sites supplémentaires propriétaires et partenaires de Monrol répartis entre l’Europe de l’Est et la région MENA, la finalisation de l’opération permet à Curium d’élargir son réseau PET, qui passe ainsi de 34 à 46 sites en Europe occidentale et en Asie. En outre, l’infrastructure industrielle et vouée à la logistique de Monrol située à Istanbul, en Turquie, ajoute une dimension significative immédiate à ses capacités de production et de distribution verticalement intégrées.

M. Chaitanya Tatineni, PDG de la branche Marchés internationaux de Curium, s'exprime en ces termes : « Nous sommes enchantés d’accueillir près de 400 nouveaux collègues engagés et hautement qualifiés au sein du groupe Curium. L’alliance entre Curium et Monrol va transformer notre envergure, nos capacités et notre portée dans plusieurs domaines clés, en particulier le Lu–177, tout en ouvrant de nouvelles perspectives pour enrichir notre offre en solutions diagnostiques et thérapeutiques qui changent la vie des patients à l’échelle mondiale. »

« Nous sommes ravis de rejoindre Curium, une entreprise dont nous admirons de longue date les capacités, le leadership et l'engagement à développer et fournir des solutions diagnostiques et thérapeutiques nucléaires de classe mondiale. » ajoute M. Aydin Kucuk, Directeur général de Monrol. Et de conclure : « Nous avons hâte de collaborer avec nos nouveaux collègues de Curium afin d'atteindre de nouveaux succès collectifs, rendus possibles par la conjugaison de notre expertise, nos connaissances et notre expérience avec l’empreinte mondiale de Curium, son portefeuille de produits et son historique d’innovation. »

Enfin, pour M. Emin Fadıllıoğlu, PDG d’Eczacıbaşı Pharmaceutical and Industrial Investment : « Nous sommes très fiers de notre partenariat avec Monrol et de l’évolution remarquable dont elle a fait preuve ces dernières années, qui l’amène aujourd’hui à rejoindre Curium, un leader mondial de la médecine nucléaire. Cette avancée témoigne de la qualité de l’entreprise, et nous sommes convaincus qu’en tirant parti d’un meilleur accès aux technologies de pointe et d'un réseau mondial étendu, elle poursuivra son essor sous la houlette de Curium. »

Pour obtenir de plus amples informations, veuillez contacter :

[email protected]

ou

Ben Valdimarsson
Reputation Inc
Portable : +44 (0)788 9805930
E–mail : bvaldimarsson@reputation–inc.com

À propos de Curium
Curium est un leader mondial de la médecine nucléaire. Nous développons, fabriquons et commercialisons des produits radiopharmaceutiques de classe mondiale pour venir en aide aux patients du monde entier. Forts de notre riche histoire et notre approche pionnière, nous sommes en mesure d’innover, d’exceller dans notre domaine et de proposer un service inégalé.

À l'appui de ses sites industriels en Europe et aux États–Unis, Curium fournit chaque année des solutions radiopharmaceutiques SPECT, PET et thérapeutiques pour des maladies potentiellement mortelles à plus de 14 millions de patients. Le nom « Curium » fait référence à l’héritage des pionniers de la recherche sur les matériaux radioactifs, Marie et Pierre Curie, qui ont donné leur nom à l’élément radioactif curium, et souligne notre spécialisation en médecine nucléaire. Pour en savoir plus, visitez le site www.curiumpharma.com

À propos d’Eczacıbaşı–Monrol
Domiciliée à Istanbul, Monrol est une entreprise de médecine nucléaire à la pointe de l’innovation et au service du développement et de la fabrication de radio–isotopes et de produits radiopharmaceutiques de qualité conformes aux bonnes pratiques de fabrication (ou « BPF »). La société distribue les produits radiopharmaceutiques de son portefeuille de classe mondiale sur les marchés internationaux. En sa double qualité de CMO (organisation de fabrication sous contrat) et CDMO (organisation de fabrication et de développement sous contrat), Monrol fournit un accompagnement précoce au développement de ses clients et propose des services pleinement intégrés aux entreprises agiles disposant d'équipes réduites et virtuelles développant de nouveaux concepts de produits pour les essais cliniques, démontrant la preuve de concept et passant aux études sur l’homme. Monrol s’engage envers la transformation et l'amélioration du parcours des patients dans le traitement du cancer grâce à un portefeuille de produits radiopharmaceutiques qu’elle distribue dans plus de 60 pays à travers le monde. Pour en savoir plus, rendez–vous sur www.monrol.com.


GLOBENEWSWIRE (Distribution ID 9413278)

Curium Finaliza a Aquisição da Monrol como Parte do seu Plano para Expandir Significativamente a Capacidade de Lutécio-177 e Pegada PET

  • Aquisição posiciona a Curium como principal fabricante do isótopo Lu–177
  • Oferece experiência inovadora em P&D e pipeline para a Curium
  • Aprimora a cobertura geográfica e a cadeia de suprimentos SPECT & PET da Curium

PARIS, March 28, 2025 (GLOBE NEWSWIRE) — A Curium Pharma (“Curium”), líder mundial em medicina nuclear, tem o prazer de anunciar a conclusão da aquisição da Eczacıbaşı–Monrol Nuclear Products Co. (Monrol), uma empresa líder em medicina nuclear, com sede em Istambul, Turquia.

A aquisição aumenta a capacidade de fabricação da Curium de Lutécio–177 (Lu–177) para atender à crescente demanda de isótopos em todo o mundo e garantir o fornecimento para o futuro lançamento dos candidatos a medicamentos Lu–177 da Curium, para Câncer de Próstata (atualmente em desenvolvimento) e Tumores Neuroendócrinos (pendente de aprovação).

Monrol complementa e aumenta as extensas capacidades de pesquisa e desenvolvimento (P&D) da Curium durante a expansão do seu portfólio e pipeline de produtos teranósticos inovadores. Curium pretende implantar o gerador Ga–68 da Monrol globalmente no futuro, dependendo das aprovações regulatórias.

Além disso, a pegada geográfica complementar PET & SPECT da Monrol expande ainda mais a oferta da Curium. A conclusão do acordo expande a presença PET da Curium de 34 locais na Europa Ocidental e na Ásia para 46, com a adição de 12 locais parceiros e da Monrol na Europa Oriental e nas regiões MENA. Além disso, a infraestrutura de fabricação e logística da Monrol em Istambul, Turquia, adiciona imediatamente escala às capacidades de produção e distribuição verticalmente integradas da Curium.

O Sr. Chaitanya Tatineni, CEO da Curium International Markets, comentou: “Estamos muito contentes em incluir cerca de 400 novos colegas altamente qualificados e dedicados ao Curium Group. A união da Curium com a Monrol transformará nossa escala, capacidades e alcance em várias áreas críticas, em particular Lu–177, e criará várias novas oportunidades para aumentar nossa oferta de soluções diagnósticas e terapêuticas que mudam a vida dos pacientes em todo o mundo.”

O Sr. Aydin Kucuk Gerente Geral da Monrol acrescentou: “Estamos entusiasmados de fazer parte da Curium. Há muito tempo admiramos a capacidade, a liderança e o compromisso da empresa em desenvolver e fornecer soluções e terapias de diagnóstico nuclear de classe mundial. Queremos trabalhar com nossos novos colegas da Curium e utilizar nossos sucessos até agora, integrando nossa expertise, conhecimento e experiência com a presença global, portfólio de produtos e histórico de inovação da Curium.”

Emin Fadıllıoğlu, CEO da Eczacıbaşı Pharmaceutical and Industrial Investment, disse: “Temos muito orgulho da nossa associação com a Monrol e da sua transformação nos últimos anos, e vê–la fazer parte da Curium, líder mundial em medicina nuclear. Este é um grande reflexo da qualidade da empresa, e acreditamos que eles continuarão a prosperar com a marca Curium, beneficiando–se de um maior acesso à tecnologia avançada e de uma extensa rede global.”

Para mais informações:

[email protected]

ou

Ben Valdimarsson
Reputation Inc
Cel.: +44 (0)788 9805930
Email: bvaldimarsson@reputation–inc.com

Sobre a Curium
A Curium é líder mundial em medicina nuclear. Desenvolvemos, fabricamos e distribuímos produtos radiofarmacêuticos de classe mundial para ajudar pacientes em todo o mundo. Nossa herança comprovada combinada com uma abordagem pioneira são as principais características para a oferta de inovação, excelência e serviço inigualável.

Com instalações de fabricação na Europa e nos Estados Unidos, a Curium oferece soluções radiofarmacêuticas de SPECT, PET e terapêuticas para doenças potencialmente fatais a mais de 14 milhões de pacientes anualmente. O nome ‘Curium’ é uma homenagem ao legado dos pioneiros pesquisadores de materiais radioativos Marie e Pierre Curie, que deram nome ao elemento radioativo cúrio, enfatizando nosso foco na medicina nuclear. Para mais informações, visite www.curiumpharma.com

Sobre a Monrol
Com sede em Istambul, a Monrol é uma empresa de medicina nuclear líder em inovação para o desenvolvimento e fabricação de radioisótopos e radiofármacos de classe GMP. A Monrol distribui seu portfólio de produtos radiofarmacêuticos de classe mundial nos mercados globais. Como CMO e CDMO, a Monrol fornece suporte de desenvolvimento inicial aos clientes e oferece serviços totalmente integrados para empresas virtuais criativas e enxutas, levando novos conceitos de produtos para ensaios clínicos, demonstrando prova de conceito e entrando em estudos inéditos em humanos. A Monrol está comprometida em transformar e aprimorar a jornada do paciente no tratamento do câncer por meio de um portfólio de produtos radiofarmacêuticos distribuídos em mais de 60 países do mundo. Para mais informações, visite www.monrol.com.


GLOBENEWSWIRE (Distribution ID 9413278)

Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab

  • Dies positioniert Curium als führenden Hersteller des Isotops Lu–177
  • Integration innovativer F&E–Expertise und Pipeline für Curium
  • Verbesserung der geografischen Abdeckung und Lieferkette von Curium für SPECT und PET

PARIS, March 29, 2025 (GLOBE NEWSWIRE) — Curium Pharma („Curium“), ein weltweit führendes Unternehmen im Bereich der Nuklearmedizin, freut sich, den Abschluss der Übernahme von Eczacıbaşı–Monrol Nuclear Products Co. (Monrol), einem führenden Unternehmen in der Nuklearmedizin mit Sitz in Istanbul, Türkei, bekanntzugeben.

Die Übernahme erhöht die Produktionskapazität von Curium für Lutetium–177 (Lu–177), um die weltweit steigende Nachfrage nach Isotopen zu decken und die Versorgung für die zukünftige Markteinführung der Lu–177–Arzneimittelkandidaten von Curium für Prostatakrebs (derzeit in der Entwicklung) und neuroendokrine Tumore (Zulassung steht noch aus) sicherzustellen.

Monrol ergänzt und erweitert die umfangreichen Forschungs– und Entwicklungskapazitäten (F&E) von Curium, während das Unternehmen sein Portfolio und seine Pipeline innovativer theranostischer Produkte weiter ausbaut. Curium beabsichtigt, den Ga–68–Generator von Monrol in Zukunft weltweit einzusetzen, vorbehaltlich der behördlichen Genehmigungen.

Darüber hinaus erweitert die komplementäre geografische Präsenz von Monrols PET & SPECT das Angebot von Curium. Mit Abschluss der Transaktion erweitert Curium seine Präsenz im Bereich der Positronen–Emissions–Tomographie (PET) von 34 Standorten in Westeuropa und Asien auf 46, da 12 Monrol–eigene und partnerschaftlich betriebene Standorte in Osteuropa sowie Nordafrika und Nahost hinzukommen. Darüber hinaus erweitert die Fertigungs– und Logistikinfrastruktur von Monrol in Istanbul, Türkei, die vertikal integrierten Produktions– und Vertriebskapazitäten von Curium sofort.

Chaitanya Tatineni, CEO International Markets von Curium, kommentierte dies wie folgt: „Wir freuen uns, fast 400 hochqualifizierte und engagierte neue Kollegen in der Curium Group willkommen zu heißen. Der Zusammenschluss von Curium und Monrol wird unsere Größe, unsere Fähigkeiten und unsere Reichweite in mehreren kritischen Bereichen, insbesondere Lu–177, verändern und zahlreiche neue Möglichkeiten schaffen, unser Angebot an lebensverändernden diagnostischen und therapeutischen Lösungen für Patienten auf der ganzen Welt zu verbessern.“

Aydin Kucuk, General Manager bei Monrol, fügte hinzu: „Wir freuen uns, Curium beizutreten, und haben die Fähigkeiten, die Führungsqualitäten und das Engagement des Unternehmens bei der Entwicklung und Bereitstellung erstklassiger nuklearer Diagnoselösungen und Therapien schon lange bewundert. Wir freuen uns darauf, mit unseren neuen Kollegen bei Curium zusammenzuarbeiten, um auf unseren bisherigen gemeinsamen Erfolgen aufzubauen, indem wir unser Fachwissen, unsere Kenntnisse und unsere Erfahrung mit der globalen Präsenz, dem Produktportfolio und der Innovationsbilanz von Curium verbinden.“

Emin Fadıllıoğlu, CEO von Eczacıbaşı Pharmaceutical and Industrial Investment, dazu: „Wir sind sehr stolz auf unsere Zusammenarbeit mit Monrol und die Veränderungen, die das Unternehmen in den letzten Jahren durchlaufen hat. Heute ist Monrol Teil von Curium, einem weltweit führenden Unternehmen in der Nuklearmedizin. Dies ist ein großartiger Beweis für die Qualität des Unternehmens, und wir glauben, dass es unter der Eigentümerschaft von Curium weiterhin florieren und von einem besseren Zugang zu fortschrittlicher Technologie und einem umfangreichen globalen Netzwerk profitieren wird.“

Weitere Informationen:

[email protected]

oder

Ben Valdimarsson
Reputation Inc
Mobil: +44 (0)788 9805930
E–Mail: bvaldimarsson@reputation–inc.com

Über Curium
Curium ist ein weltweit führendes Unternehmen im Bereich der Nuklearmedizin. Wir entwickeln, produzieren und vertreiben erstklassige radiopharmazeutische Produkte, die Patienten auf der ganzen Welt helfen. Unser bewährtes Erbe, kombiniert mit einem bahnbrechenden Ansatz, ist das Markenzeichen für Innovation, Exzellenz und einen unvergleichlichen Service.

Mithilfe seiner Produktionsstätten in Europa und den Vereinigten Staaten liefert Curium SPECT–, PET– und therapeutische radiopharmazeutische Lösungen für lebensbedrohliche Krankheiten an über 14 Millionen Patienten jährlich. Der Name „Curium“ ehrt das Erbe der Pioniere in der Erforschung radioaktiver Materialien, Marie und Pierre Curie, nach denen das radioaktive Element Curium benannt wurde, und unterstreicht unsere Ausrichtung auf die Nuklearmedizin. Weitere Informationen finden Sie unter www.curiumpharma.com

Über Monrol
Monrol ist ein Unternehmen im Bereich der Nuklearmedizin mit Hauptsitz in Istanbul, das bei der Entwicklung und Herstellung von GMP–konformen Radioisotopen und Radiopharmazeutika führend ist. Monrol vertreibt sein erstklassiges Portfolio an Radiopharmazeutika auf den globalen Märkten. Als CMO und CDMO unterstützt Monrol seine Kunden in der frühen Entwicklungsphase und bietet vollständig integrierte Dienstleistungen für schnell agierende, schlanke, virtuelle Unternehmen, die neue Produktkonzepte in die klinische Erprobung bringen, den Nachweis des Konzepts erbringen und die ersten Studien am Menschen durchführen möchten. Monrol hat sich zum Ziel gesetzt, die Behandlung von Krebspatienten durch ein Portfolio von radiopharmazeutischen Produkten, die in mehr als 60 Ländern weltweit vertrieben werden, zugunsten der Patienten zu verändern und zu verbessern. Weitere Informationen finden Sie unter www.monrol.com.


GLOBENEWSWIRE (Distribution ID 9413278)

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

  • Positions Curium as leading manufacturer of Lu–177 isotope
  • Brings innovative R&D expertise and pipeline to Curium
  • Enhances Curium’s SPECT & PET geographical coverage and supply chain

PARIS, March 28, 2025 (GLOBE NEWSWIRE) — Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı–Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.

The acquisition enhances Curium’s manufacturing capacity of Lutetium–177 (Lu–177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu–177 drug candidates, for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pending approval).

Monrol complements and adds to Curium’s extensive research & development (R&D) capabilities as it continues to expand its portfolio and pipeline of innovative theranostic products. Curium intends to deploy Monrol’s Ga–68 generator globally in the future, pending regulatory approvals.

In addition, Monrol’s PET & SPECT complementary geographic footprint further expands Curium’s offering. The completion of the deal expands Curium’s PET footprint of 34 sites in Western Europe and Asia to 46 with the addition of 12 Monrol owned and partnered sites in Eastern Europe and MENA regions. Furthermore, Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, immediately adds scale to Curium’s vertically integrated production and distribution capabilities.

Mr. Chaitanya Tatineni, Curium’s CEO International Markets commented: “We are delighted to welcome close to 400 highly–skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu–177, and create multiple new opportunities to enhance our offering of life–changing diagnostic and therapeutic solutions to patients around the world.”

Mr. Aydin Kucuk General Manager at Monrol added: “We are excited to be joining Curium and have long admired the company’s capabilities, leadership and commitment to developing and supplying world–class nuclear diagnostics solutions and therapies. We look forward to working with our new Curium colleagues to build on our joint successes to date by integrating our expertise, knowledge and experience with Curium’s global footprint, product portfolio, and track record of innovation.”

Mr. Emin Fadıllıoğlu, CEO, Eczacıbaşı Pharmaceutical and Industrial Investment, said: “We are very proud of our association with Monrol and its transformation in recent years, which today sees them become part of Curium, a world–leader in nuclear medicine. This is a great reflection of the quality of the business, and we believe they will continue to thrive under the ownership of Curium, benefiting from greater access to advanced technology and an extensive global network.”

For more information:

[email protected]

or

Ben Valdimarsson
Reputation Inc
Mob: +44 (0)788 9805930
Email: bvaldimarsson@reputation–inc.com

About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world–class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life–threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world–class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first–in–human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com.


GLOBENEWSWIRE (Distribution ID 9412464)

Nordic Capital Finaliza Aquisição da Anaqua

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) — A Anaqua, fornecedora líder de soluções e serviços de tecnologia de gerenciamento de inovação e propriedade intelectual (IP), anunciou hoje que a Nordic Capital, uma experiente investidora de capital privado em Tecnologia e Pagamentos em todo o mundo, adquiriu uma participação majoritária na Anaqua da Astorg.

A aquisição representa um investimento estratégico fundamental da Nordic Capital, focado em impulsionar o crescimento contínuo da Anaqua através do desenvolvimento de soluções de gestão de IP cada vez mais inovadoras. A Nordic Capital apoiará a expansão global da Anaqua e as melhorias contínuas nos seus melhores recursos operacionais e de software para fortalecer ainda mais a posição da empresa no mercado. As plataformas diferenciadas da Anaqua, AQX® e PATTSY WAVE®, integram fluxos de trabalho de melhores práticas, análise de dados, registros estrangeiros e pagamentos de renovação de patentes e marcas registradas em plataformas de software únicas e de missão crítica para profissionais de IP. As plataformas oferecem propostas completas de valor exclusivas para agilizar as operações, informar a estratégia e capacitar a tomada de decisões em torno dos valiosos portfólios de IP dos clientes.

A Nordic Capital tem mais de 20 anos de experiência em acelerar o crescimento de empresas de tecnologia inovadoras e fez 33 investimentos em tecnologia em empresas com um valor agregado de cerca de 26 mil milhões de euros.

“A Nordic Capital será um grande parceiro no futuro – tanto para a Anaqua quanto para nossos clientes – com nossa visão compartilhada de plataformas de gerenciamento de IP lideradas por software que podem impulsionar a transformação do setor”, comentou o CEO da Anaqua, Bob Romeo. Justin Crotty, COO da Anaqua, acrescentou: “A Nordic Capital será fundamental para a Anaqua concretizar a nossa estratégia de crescimento e fornecer soluções orientadas para a tecnologia para os nossos clientes e para o mercado de IP.”

Fredrik Näslund, Sócio e Chefe de Tecnologia e Pagamentos da Nordic Capital Advisors, comentou: “Estamos prontos para apoiar a Anaqua na sua próxima fase de crescimento, ajudando ainda mais na expansão da sua presença global e estabelecendo a plataforma líder de gestão de IP para indústrias orientadas para a inovação.”

Sobre a Anaqua

A Anaqua, Inc. é fornecedora premium de soluções e serviços de tecnologia integrada para o gerenciamento de propriedade intelectual (IP). As plataformas de gerenciamento de IP AQX® e PATTSY WAVE® da Anaqua combinam fluxos de trabalho de melhores práticas com análise de big data e serviços habilitados para tecnologia, para a criação de um ambiente inteligente que informa as estratégias de IP, permite decisões de IP e simplifica os processos de IP. Atualmente quase metade dos 100 principais candidatos a patentes e marcas globais dos EUA, bem como um número crescente de escritórios de advocacia em todo o mundo, usam as soluções da Anaqua. Mais de dois milhões de executivos, advogados, assistentes jurídicos, administradores e inovadores de IP usam a plataforma para gerenciamento de IP. A sede da empresa está localizada em Boston, com escritórios adicionais nos Estados Unidos, Europa, Ásia e Austrália. Para mais informações, visite anaqua.com ou LinkedIn.

Sobre a Nordic Capital

A Nordic Capital é uma investidora de patrimônio privado líder especializada no setor, com um compromisso firme com a criação de negócios mais fortes e sustentáveis por meio da melhoria operacional e do crescimento transformador. A Nordic Capital concentra–se em regiões e setores selecionados onde tem uma experiência profunda e uma longa história. Os setores de foco são Saúde, Tecnologia e Pagamentos, Serviços Financeiros, e Serviços e Tecnologia Industrial. As principais regiões são a Europa e o mundo para investimentos em Saúde, e Tecnologia e Pagamentos. Desde o início em 1989, a Nordic Capital já investiu aproximadamente 26 mil milhões de euros em cerca de 150 investimentos. As entidades mais recentes são a Nordic Capital XI com 9,0 mil milhões de euros em capital comprometido e a Nordic Capital Evolution II com 2 mil milhões de euros em capital comprometido, principalmente de investidores institucionais internacionais, como fundos de pensões. A Nordic Capital Advisors tem escritórios locais na Suécia, Reino Unido, EUA, Alemanha, Dinamarca, Finlândia, Noruega e Coreia do Sul. www.nordiccapital.com.

“Nordic Capital” refere–se, dependendo do contexto, a qualquer uma ou todas as entidades, veículos, estruturas e entidades associadas à marca Nordic Capital. Os sócios gerais e/ou gestores de carteiras representantes das entidades e veículos da Nordic Capital são aconselhados por várias entidades sub–consultoras não discricionárias, algumas ou todas referidas como “Nordic Capital Advisors”.

Contato com a Empresa:
Nancy Hegarty
VP, Marketing
Anaqua
617–375–2655
[email protected]


GLOBENEWSWIRE (Distribution ID 9385213)

Nordic Capital completes acquisition of Anaqua

BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Anaqua, a leading provider of innovation and intellectual property (IP) management technology solutions and services, today announced that Nordic Capital, an experienced private equity investor in Technology & Payments globally, has acquired a controlling interest in Anaqua from Astorg.

The acquisition represents a key strategic investment by Nordic Capital, focused on driving continued growth for Anaqua through the development of increasingly innovative IP management solutions. Nordic Capital will support Anaqua’s global expansion and ongoing enhancements to its best–in–class software and operational capabilities to further strengthen the company’s market position. Anaqua’s differentiated platforms, AQX® and PATTSY WAVE®, integrate best–practice workflows, data analytics, foreign filings, and patent and trademark renewal payments into single, mission–critical software platforms for IP professionals. The platforms offer unique end–to–end value propositions to streamline operations, inform strategy, and empower decision–making around customers’ valuable IP portfolios.

Nordic Capital has over 20 years of experience accelerating the growth of innovative technology companies and has made 33 technology investments in companies with an aggregate enterprise value of circa EUR 26 billion.

“Nordic Capital will be a great partner going forward – both for Anaqua and our customers –with our shared vision of software–led IP management platforms that can drive industry transformation,” commented Anaqua CEO Bob Romeo. Justin Crotty, Anaqua COO, added: “Nordic Capital will be instrumental in Anaqua realizing our growth strategy and delivering technology driven solutions for our customers and the IP market.”

Fredrik Näslund, Partner and Head of Technology & Payments, at Nordic Capital Advisors, commented: “We look forward to supporting Anaqua in its next phase of growth, helping them to expand their global footprint further and establishing the leading IP management platform for innovation–driven industries.”

About Anaqua
Anaqua, Inc. is a premium provider of integrated technology solutions and services for the management of intellectual property (IP). Anaqua's AQX® and PATTSY WAVE® IP management platforms combine best practice workflows with big data analytics and technology–enabled services to create an intelligent environment that informs IP strategies, enables IP decisions and streamlines IP processes. Today, nearly half of the 100 largest U.S. patent applicants and global brands, as well as a growing number of law firms worldwide, use Anaqua's solutions. Over two million IP executives, lawyers, paralegals, administrators and innovators use the platform for their IP management. The company is headquartered in Boston, with additional offices in the United States, Europe, Asia, and Australia. For more information, please visit anaqua.com or LinkedIn.

About Nordic Capital
Nordic Capital is a leading sector–specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 26 billion in close to 150 investments. The most recent entities are Nordic Capital XI with EUR 9.0 billion in committed capital and Nordic Capital Evolution II with EUR 2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. www.nordiccapital.com.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non–discretionary sub–advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

Company Contact:
Nancy Hegarty
VP, Marketing
Anaqua
617–375–2655
[email protected]


GLOBENEWSWIRE (Distribution ID 9384267)

Nordic Capital achève l'acquisition d'Anaqua

BOSTON, 25 févr. 2025 (GLOBE NEWSWIRE) — Anaqua, un fournisseur de premier plan de services et de technologies de gestion de l'innovation et de la propriété intellectuelle, a annoncé aujourd'hui que Nordic Capital, un investisseur privé expérimenté dans les technologies et les paiements à l’échelle mondiale, a acquis une participation majoritaire dans Anaqua auprès d'Astorg.

Cette acquisition représente un investissement stratégique clé pour Nordic Capital, qui entend poursuivre la croissance d'Anaqua en développant des solutions de gestion de la propriété intellectuelle de plus en plus innovantes. Nordic Capital soutiendra l'expansion mondiale d'Anaqua et l'amélioration continue de ses logiciels ainsi que de ses capacités opérationnelles afin de renforcer la position de l'entreprise sur le marché. Les plateformes AQX® et PATTSY WAVE® d'Anaqua sont des solutions logicielles tout–en–un et essentielles pour les professionnels de la propriété intellectuelle. Elles se distinguent par le recours aux meilleures pratiques pour optimiser les flux de travail, par leur capacité d'analyse des données, et par l’intégration de services d’extension de brevets à l’international et de paiements de renouvellement des brevets et des marques. Ces plateformes proposent des solutions uniques et complètes pour aider les clients à optimiser les opérations, à élaborer une stratégie et à améliorer la prise de décision concernant leurs portefeuilles de propriété intellectuelle.

Nordic Capital a plus de 20 ans d'expérience dans l'accélération de la croissance des entreprises technologiques innovantes et a réalisé 33 investissements technologiques dans des entreprises, pour un montant total d'environ 26 milliards d'euros.

« Nordic Capital sera un excellent partenaire pour Anaqua et nos clients. Nous partageons la même vision : développer des plateformes logicielles de gestion de la propriété intellectuelle qui permettront de transformer l'industrie », a commenté Bob Romeo, PDG d'Anaqua. Justin Crotty, COO d'Anaqua, a ajouté : « Nordic Capital jouera un rôle déterminant dans la mise en œuvre de la stratégie de croissance d'Anaqua et l’offre de solutions technologiques pour nos clients et le marché de la propriété intellectuelle ».

Fredrik Näslund, associé et responsable de la technologie et des paiements chez Nordic Capital Advisors, a commenté : « Nous sommes impatients de soutenir Anaqua dans sa prochaine phase de croissance, en l'aidant à étendre son implantation mondiale et à devenir la principale plateforme de gestion de la propriété intellectuelle pour les entreprises innovantes. »

À propos d'Anaqua
Anaqua, Inc. est un fournisseur de premier plan de solutions et services technologiques intégrés de gestion de la propriété intellectuelle (PI). Ses logiciels, AQX® et PATTSY WAVE®, combinent les meilleurs outils pour définir une stratégie de propriété intellectuelle avisée. Ses technologies, qui reposent notamment sur des workflows et des capacités d’analyses avancées, offre un environnement de travail intelligent conçu pour prendre de meilleures décisions et optimiser les opérations de PI. Aujourd'hui, près de la moitié des 100 premiers déposants de brevets américains et des marques mondiales, ainsi qu'un nombre croissant de cabinets de conseils dans le monde utilisent les solutions Anaqua. Plus d'un million de décideurs, avocats, parajuristes, gestionnaires et innovateurs utilisent la plateforme pour leurs besoins de gestion de la PI. Le siège de la société est situé à Boston, avec des bureaux aux Etats–Unis, en Europe, en Asie et en Australie. Pour plus d’informations, veuillez consulter le site anaqua.com ou LinkedIn.

À propos de Nordic Capital
Nordic Capital est un investisseur en capitaux privés qui s'engage à créer des entreprises durables plus fortes grâce à l'amélioration opérationnelle et à la croissance transformatrice. Nordic Capital se concentre sur certains secteurs et régions où la société possède une expérience approfondie et une longue histoire. Les secteurs sur lesquels elle se concentre sont la santé, les technologies et les paiements, les services financiers, les services et les technologies industrielles. Ses régions clés sont l'Europe et le monde pour les investissements dans les secteurs de la santé et des technologies et des paiements. Depuis sa création en 1989, Nordic Capital a investi environ 26 milliards d'euros dans près de 150 placements. Les fonds les plus récents sont Nordic Capital XI, avec 9 milliards d'euros de capital engagé, et Nordic Capital Evolution II, avec 2 milliards d'euros de capital investi, apporté principalement par des investisseurs institutionnels internationaux, tels que des fonds de pension. Nordic Capital Advisors dispose de bureaux locaux en Suède, au Royaume–Uni, aux États–Unis, en Allemagne, au Danemark, en Finlande, en Norvège et en Corée du Sud. www.nordiccapital.com.

“Nordic Capital” désigne, selon le contexte, tout ou partie des entités, véhicules, structures et entités associées de la marque Nordic Capital. Les commandités et/ou les gestionnaires de portefeuille délégués des entités et des véhicules de Nordic Capital sont conseillés par plusieurs entités de sous–conseils non discrétionnaires, dont certaines ou toutes sont désignées sous le nom de ” Nordic Capital Advisors “.

Contact presse :
Nancy Hegarty
Vice–président, Marketing
+1–617–375–2655
[email protected]


GLOBENEWSWIRE (Distribution ID 9384267)